Kiadis Pharma strengthens core team with three senior appointments
08 Novembro 2018 - 4:00AM
Amsterdam, The Netherlands, November 8, 2018 -
Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext
Amsterdam and Brussels: KDS), a clinical-stage
biopharmaceutical company, today announces that it has appointed
three new senior team members to further strengthen the Company as
it transitions into commercial stage. Mr. Dirk De Naeyer has been
appointed Head of Supply Chain, Mr. Jonathan Sweeting has been
appointed Head of Commercial Europe and Mr. Marcel Zwaal has been
appointed Head of Corporate Development.
Arthur Lahr, CEO of
Kiadis Pharma, commented: "I am delighted to
welcome Dirk De Naeyer, Jonathan Sweeting and Marcel Zwaal to
Kiadis. Building a biotech company requires
highly experienced people across all disciplines. With Dirk,
Jonathan and Marcel joining our team we have succeeded in
attracting yet more highly experienced international talents to
develop and commercialize ATIR101 and build out Kiadis. These
appointments confirm our ability to attract seasoned senior
executives to deliver on our strategy."
Mr. Dirk De
Naeyer joins Kiadis Pharma as Head of Supply Chain from Janssen
Pharmaceuticals where he spent 14 years in various leadership
positions. Most recently, he was co-lead for the integration of
Actelion into Janssen. Prior to that, he was the head of the
Janssen Global Clinical Operations team and held multiple supply
chain and operations leadership positions. This included heading up
the Janssen Clinical Supply Chain, overseeing all active
pharmaceutical ingredient (API) and Drug Product manufacturing,
Packaging and Distribution for Janssen R&D, which covered Small
Molecules, Biologics and Stem Cell therapies. Mr. De Naeyer joined
Janssen after five years at McKinsey. He holds a degree in
Engineering from the KU Leuven, Belgium, and an MBA from the
University of Chicago. Mr. De Naeyer is a Belgian citizen.
Mr. Jonathan
Sweeting joins Kiadis Pharma as Head of Commercial Europe.
Prior to this he spent over five years at GSK in various leadership
positions, most recently as Senior Vice President and Head of the
Global Respiratory Franchise and previously in roles as General
Manager Poland and Global Commercialization Leader for Respiratory
Biologics. Mr. Sweeting joined GSK from AstraZeneca where he spent
over eight years in global and local roles in the UK and Russia.
Prior to that he was at Accenture for five years. Mr. Sweeting
holds an MA (Hons) degree in Chemistry from the University of
Cambridge and an MBA from INSEAD. Mr. Sweeting is a British
citizen.
Mr. Marcel
Zwaal joins Kiadis Pharma as Head of Corporate Development from
his previous role as CEO of Hubrecht Organoid Technologies. Before
that Marcel worked in Corporate Development at Galapagos, served as
CEO of cell therapy biotech startup DCPrime and held several senior
management positions at Crucell in finance and business development
prior to its acquisition by Johnson & Johnson in 2011. Mr.
Zwaal has over 20 years' experience in finance and business, 10
years of which has focused on medical innovation and biotechnology.
He holds an Executive Master of Finance and Control degree and a
Finance BA Master's degree from Vrije Universiteit Amsterdam. Mr.
Zwaal is a Dutch citizen.
For more information, please
contact:
Kiadis Pharma:
Karl Hård, Head of Investor Relations &
Communications
Tel. +31 611 096 298
k.hard@kiadis.com |
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 714 1789
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com
|
About Kiadis
Pharma
Kiadis Pharma is developing its lead product candidate, ATIR101,
for use in conjunction with haploidentical (genetically
half-matched) hematopoietic stem-cell transplantations (HSCT) for
adult blood cancers to address key limitations of haploidentical
HSCT, without prophylactic immunosuppression and its associated
morbidity and mortality. Based on the positive results from the
single dose Phase 2 CR-AIR-007 study, the Company submitted a
marketing authorization application to the European Medicines
Agency in April 2017 for approval of ATIR101 as an adjunctive
treatment in haploidentical HSCT for high risk adult hematological
malignancies. If the product is conditionally approved, Kiadis
Pharma intends to launch ATIR101 through its own commercial
organization in a first EU member state in the second half of
2019.
In December 2017, Kiadis Pharma
commenced an international, multicenter, randomized and controlled
Phase 3 clinical trial of ATIR101 against the Post-Transplant
Cyclophosphamide, (PTCy) protocol, the main protocol used to
perform a haploidentical HSCT. The trial will be performed in 250
patients with acute leukemia and myelodysplastic syndrome at
approximately 50 sites in the United States, Canada, Europe and
certain additional countries. ATIR101 received regenerative
medicine advanced therapy (RMAT) designation from the FDA in
September 2017, which provides benefits that are materially
equivalent to a Breakthrough Therapy designation from the FDA. In
addition, ATIR101 has been granted multiple orphan drug
designations both in the European Union and the United States.
The Company's shares are listed on
Euronext Amsterdam and Brussels under the ticker KDS.
Forward Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance or results to
differ significantly from any anticipated development. Forward
looking statements contained in this press release regarding past
trends or activities should not be taken as a representation that
such trends or activities will continue in the future. As a result,
Kiadis Pharma expressly disclaims any obligation or undertaking to
release any update or revisions to any forward-looking statements
in this press release as a result of any change in expectations or
any change in events, conditions, assumptions or circumstances on
which these forward-looking statements are based. Neither Kiadis
Pharma nor its advisers or representatives nor any of its
subsidiary undertakings or any such person's officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking
statements contained in this press release or the actual occurrence
of the forecasted developments. You should not place undue reliance
on forward-looking statements, which speak only as of the date of
this press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire